Cingulate Inc

CING

Company Profile

  • Business description

    Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

  • Contact

    1901 West 47th Place
    KansasKS66205
    USA

    T: +1 913 942-2300

    https://www.cingulate.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    13

Stocks News & Analysis

stocks

Undervalued ASX share hampered by delays in foreign expansion

A near monopoly in Australia pushes this company into global markets but progress has been slow.
stocks

Ask the analyst: Why has MinRes fallen so far?

Mineral Resources shares are down almost 50% year to date. Mark Taylor weighs in on some of the reasons why.
stocks

The largest ASX company is materially overvalued

After a 37% share price increase in the last 12 months, investors may be too optimistic for this ASX giant 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,518.9033.70-0.39%
CAC 407,426.8888.211.20%
DAX 4019,448.60233.121.21%
Dow JONES (US)44,295.49306.500.70%
FTSE 1008,125.1952.800.65%
HKSE20,426.93301.26-1.45%
NASDAQ19,284.891.89-0.01%
Nikkei 22539,533.3232.950.08%
NZX 50 Index12,686.3384.00-0.66%
S&P 5005,999.704.160.07%
S&P/ASX 2008,266.2028.90-0.35%
SSE Composite Index3,470.0717.770.51%

Market Movers